Top Investigators Explore the Complexities of Angiogenesis Cancer Research
The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.
Compiles the results of four decades of progress
Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject.
This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.
"… a timely and worthwhile study of the complexities of the clinical application of angiogenesis inhibitors. … the most comprehensive of its kind, is nicely tempered in its assessments of both the triumphs of antiangiogenic tumor therapy and the gaps in knowledge that impede further successful treatments. The editors and contributors of this book … are leaders in the field. The topics covered … are well chosen and present the reader with balanced discussions … . This authoritative book should be required reading for anyone interested in tumor angiogenesis."
— Joshua I. Greenberg, M.D. & David A. Cheresh, Ph.D., University of California, San Diego, La Jolla in The New England Journal of Medicine, July 2008
"It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject."
– In Anticancer Research, 2009, Vol. 29
Table of Contents
PART I. ANGIOGENESIS IN CANCER
Strategies to Prolong the Nonangiogenic Dormant State of Human Cancer; George N. Naumov and Judah Folkman
Vascular Endothelial Growth Factor: Basic Biology and Clinical Implications; Napoleone Ferrara
Angiogenesis in Solid Tumors; Rakesh K. Jain and Dan G. Duda
Pathophysiologic Role of VEGF in Hematologic Malignancies; Klaus Podar, Shaji Kumar, Dharminder Chauhan, and Kenneth C. Anderson
Tumor Microenvironment and Angiogenesis; Cheryl H. Baker and Isaiah J. Fidler
PART II. TARGETING ANGIOGENESIS FOR CANCER THERAPY
Tyrosine Kinase Inhibitors of Angiogenesis; Janessa J. Laskin and Alan B. Sandler
Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy; Zhenping Zhu and Daniel J. Hicklin
Targeting Fibroblast Growth Factor/Fibroblast Growth Factor Receptor System in Angiogenesis; Marco Rusnati and Marco Presta
Development of the VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and Discovery of the Next Generation of Angiogenesis Targets; John S. Rudge, Gavin Thurston, Samuel Davis, Nicholas Papadopoulos, Nicholas W. Gale, Stanley J. Wiegand, and George D. Yancopoulos
Proteinases and Their Inhibitors in Angiogenesis; Yves A. DeClerck, Khalid Bajou, and Walter E. Laug
Prostaglandins and COX-2: Role in Antiangiogenic Therapy; Kristin Hennenfent, Daniel Morgensztern, and Ramaswamy Govindan
Integrins, Adhesion, and Coadhesion Inhibitors in Angiogenesis; Abebe Akalu and Peter C. Brooks
Conventional Therapeutics with Antiangiogenic Activity; Christian Hafner, Thomas Vogt, and Albrecht Reichle
Vascular Disrupting Agents; David J. Chaplin, Graeme J. Dougherty, and Dietmar W. Siemann
Vascular and Hematopoietic Stem Cells as Targets for Antiangiogenic Therapy; Shahin Rafii
Genetic Strategies for Targeting Angiogenesis; Anita Tandle, Mijung Kwon, and Steven K. Libutti
Identification of New Targets Using Expression Profiles; Thomas R. Burkard, Zlatko Trajanoski, Maria Novatchkova, Hubert Hackl, and Frank Eisenhaber
PART III. TRANSLATING ANGIOGENESIS INHIBITORS TO THE CLINIC
Clinical Trial Design and Regulatory Issues; Ramzi N. Dagher and Richard Pazdur
Surrogate Markers for Antiangiogenic Cancer Therapy; Darren W. Davis
Noninvasive Surrogates; Bruno Morgan and Mark A. Horsfield
Pharmacodynamic Markers in Tissues; Darren W. Davis
Blood-Based Biomarkers for VEGF Inhibitors; Amado J. Zurita, Hua-Kang Wu, and John V. Heymach
PART IV. TREATMENT OF SPECIFIC CANCERS WITH ANGIOGENESIS INHIBITORS
Antiangiogenic Therapy for Colorectal Cancer; Paulo M. Hoff and Everardo D. Saad
Combined Modality Therapy of Rectal Cancer; Christopher G. Willett and Dan G. Duda
Antiangiogenic Therapy for Breast Cancer; Pablo M. Bedano, Brian P. Schneider, Kathy D. Miller, and George W. Sledge Jr.
Antiangiogenic Therapy for Lung Malignancies; David J. Stewart
Antiangiogenic Therapy for Prostate Cancer; Leslie K. Walker, Glenn Liu, and George Wilding
Antiangiogenic Therapy for Hematologic Malignancies; Karen W.L. Yee and Francis J. Giles
Antiangiogenic Therapy for Gliomas; Heinrich Elinzano and Howard A. Fine
Antiangiogenic Therapy for Kaposi’s Sarcoma; Henry B. Koon, Liron Pantanowitz, and Bruce J. Dezube
Antiangiogenic Therapy for Melanoma; Keith Dredge and Angus G. Dalgleish
Sunitinib and Renal Cell Carcinoma; Robert J. Motzer and Sakina Hoosen